Roberto Menicagli has completed his PhD at the age of 25 years from Milan University .Postdoctoral studies in biochemistry and molecular genetics, at the faculty of biology at Milan University, where, two years he has been ,a contract professor He is the director of Roma Biomed Research Lab a Private Medical Service Organization. Has published more than 20 papers in reputed journals ,some also with impact factor ; is also the principal author of 4 international patent ,in the field of the environment, and of the biomarkers applications ;has beenrn rnserving as an editorial board member of two magazine concerning the medical sciences. rn

The Possibility of Employ the Micronucleus test for the diagnosis of the doubt cases in the screening for the determination of Breast Cancerrn rnMenicagli Roberto *- RomaBiomedResearch, Lab rnMenicagli Laura**- Esseridou Anastassia-, IRCCS .Policlinico San Donato-Department of Radiodiagnostic, University of Milan,rn rnIntroduction and Objectives: The aim of this study is to check the possibility to use the test with micronuclei in saliva, for cases doubts, (BIRADS 3), detected in screening for breast cancer.rnMaterial and Methods : It is been executed a bibliographic search, in free text, and with the cross referring , on Pub Med, for articles published from Jan 1, 2000 to Dec 31, 2016,for the keywords : \"micronuclei in exfoliated buccal cells in breast cancer“ Are also executed preliminary tests, to seven patients ,BIRADS 3,and BIRADS 2, to evaluate the difference, in the score concerning the presence of micronuclei in the two groups . For the small number of patients, these results, are not statistically reliable, but can still sufficiently show a very indicative trendrn Results: The bibliographic references, show as the micronuclei scoring can be used as a biomarker on fine needle aspiration cytology smears of breast cancer, while the tests in peripheral blood lymphocytes, have known reproducibility problem. Also the bibliography show ,in breast cancer , an increase of MN in exfoliated buccal mucosa :Five studies show that in buccal cells, in breast cancer , the amount of MN are significantly higher than compared to benign cases as in six studies for the detection of micronuclei in needle aspiration in ductal carcinoma . Contrasting results are for MN in peripheral blood lymphocytes. Concern our preliminary test in buccal cells , three patients ,of the group BIRADS 3, show to have micronuclei, while no positive findings were found in none of BIRADS 2 rnFIGURE 1-TEST FOR MICRONUCLEIrnBIRADS 3 BIRADS 2rn rnMicronucleus not MicronucleusrnConclusions: May be interesting to apply the MN scoring in cases of doubt, according to functional BI-RADS category 3 (probably benign), and which are sent to a successive controlrnREFERENCES rn1-Bolognesi, C., Bruzzi, P., Gismondi, V., Volpi, S., Viassolo, V., Pedemonte, S. and Varesco, L. 2014. Clinical application of micronucleus test: a case-control study on the prediction of breast cancer risk/susceptibility. PLoS One. 2014 Nov 21;9(11):e112354 rn2-Dey, P., Samanta, S. and Susheilia, S. 2012. Micronucleus assay in buccal smears of breast carcinoma patients; Diagn. Cytopathol. 2012 Aug;40(8):664-6. Dis Markers. 2014;2014:956835 rn3-Flores-Garcia, A., et al. 2014. Micronuclei and other nuclear anomalies in exfoliated rnRoberto Menicagli has completed his PhD at the age of 25 years from Milan University .Postdoctoral studies in biochemistry and molecular genetics, at the faculty of biology at Milan University, where, two years he has been ,a contract professor He is the director of Roma Biomed Research Lab a Private Medical Service Organization. Has published more than 20 papers in reputed journals ,some also with impact factor ; is also the principal author of 4 international patent ,in the field of the environment, and of the biomarkers applications ;has beenrn rnserving as an editorial board member of two magazine concerning the medical sciences. rn